Table 1

Clinical course of patients, in whom SEI developed after EKC, that were treated with topical 0.05% CSA eye drops
Patient Age/Sex Affected eye Initial BCVA (LogMAR) Initial IOP (mmHg) Initial CSIS Duration of follow up with Corticosteroids Therapy (month) CsA treatment for increased ocular pressure (Yes/No) Duration of follow up with 0.05% CSA Therapy (month) BCVA at last follow-up visit IOP at last follow-up visit CSIS at last follow-up visit The length of follow up without CsA (month) Recurrence after CsA treatment (Yes/No)
1 13/F RE 0.00 11 1 12 Y 1 0.00 11 0 6 N
2 38/F LE 0.00 14 1 9 N 6 0.00 12 0 5 N
3 26/F RE/LE 0.10/0.22 16/18 1/2 3/5 N 1/1 0.00/0.10 14/19 0/0 4/3 N
4 47/F RE 0.00 15 1 3 N 7 0.00 17 0 2 N
5 40/F RE 0.22 25 1 3 Y 1 0.00 20 0 4 N
6 30/M RE/LE 0.40/0.00 26/22 4/1 4/7 Y 13/8 0.20/0.00 21/19 2/0 5/3 N
7 18/M RE 0.40 23 3 6 Y 7 0.15 20 1 2 N
8 50/M RE 0.22 18 2 7 N 6 0.10 16 1 0 N
9 27/M RE/LE 0.00/0.30 15/17 1/3 8/9 N 1/1 0.00/0.15 13/16 0/0 3/3 N
10 40/F LE 0.00 19 2 4 N 7 0.00 19 0 3 Y
11 16/M RE 0.00 17 1 3 N 6 0.00 14 0 4 N
12 32/F RE 0.20 16 1 3 N 1 0.10 17 0 3 N
13 75/M RE/LE 0.00/0.20 15/22 1/2 5/4 Y 7/8 0.00/0.15 16/19 0/0 4/3 Y
14 60/F RE 0.00 20 1 11 Y 6 0.00 19 0 10 N
15 30/F RE/LE 0.40/0.30 17/21 3/2 13/8 N 10/8 0.20/0.10 15/18 1/0 12/3 N
16 22/F RE/LE 0.00/0.30 17/23 1/2 14/10 Y 1/5 0.00/0.10 17/19 0/0 6/4 N

F: Female, M: Male, RE: Right eye, LE: Left eye, Y: Yes, N:No, BCVA: Best corrected visual acuity, IOP: Intraocular pressure, CSIS: Corneal subepithelial infiltrate scores.

Okumus et al.

Okumus et al. BMC Ophthalmology 2012 12:42   doi:10.1186/1471-2415-12-42

Open Data